Viral Vectors and Plasmid DNA Manufacturing Market Trends

ID: MRFR/HC/9195-HCR

200 Pages

Rahul Gotadki

October 2025

Viral Vectors and Plasmid DNA Manufacturing Market Research Report By Application (Gene Therapy, Vaccine Development, Transgenic Research, Cell and Gene Editing), By Type (Viral Vectors, Plasmid DNA, RNA-based Vectors), By Technology (Viral Transduction, Electroporation, Microinjection, Liposomal Delivery), By End Use (Pharmaceutical Companies, Biotechnology Firms, Research Institutions) and By...

Viral Vectors and Plasmid DNA Manufacturing Market Infographic

Single User

$ 4,950.0

Multiple License

$ 5,950.0

Enterprise User

$ 7,250.0

Summary Table of Contents Segmentation Download PDF

Market Trends

Key Emerging Trends in the Viral Vectors and Plasmid DNA Manufacturing Market

The viral vectors and plasmid DNA manufacturing market is experiencing a rapid increase, pushed by the expanding discipline of gene remedies. As gene-based treatments grow to be an increasing number of possible for a range of genetic disorders and different illnesses, there's a surging demand for viral vectors and plasmid DNA to be used in gene shipping systems. Technological improvements in viral vector manufacturing are a key trend. Innovations in vector design, production processes, and optimization strategies are enhancing the efficiency and protection of gene shipping. Continuous upgrades in viral vector generation are essential for the development of effective and centered gene healing procedures. Viral vectors are finding applications beyond gene remedy, extending into regions together with vaccine development, oncolytic virotherapy, and gene enhancement. The versatility of viral vectors is using their adoption in various healing and preventive programs, broadening the scope of the viral vector production market. Single-use technologies are gaining prominence in viral vector and plasmid DNA manufacturing. The adoption of disposable bioreactors, single-use tubing, and different components reduces the chance of move-contamination, complements operational flexibility, and hastens production timelines, contributing to powerful manufacturing processes. The market is witnessing an increase in strategic collaborations and partnerships between biopharmaceutical agencies and producers of viral vectors and plasmid DNA. These collaborations intend to mix understanding, resources, and technology to accelerate the improvement and commercialization of gene-based treatments. Quality manipulation and regulatory compliance are paramount in the viral vectors and plasmid DNA manufacturing market. Manufacturers are investing in high-quality assurance measures and adhering to regulatory hints to ensure the safety, purity, and efficacy of gene therapy merchandise, fostering agreement among stakeholders. Next-generation plasmid DNA manufacturing technologies are rising to cope with scalability and price challenges. Continuous efforts are being made to improve plasmid DNA yield, lessen manufacturing expenses, and decorate the general performance of plasmid DNA production tactics. The globalization of gene therapy medical trials is influencing the distribution and production of viral vectors and plasmid DNA on a worldwide scale. Manufacturers are adapting to the increasing geographical diversity of gene therapy research and development sports, making sure accessibility and well-timed shipping of critical additives are available. Process intensification is an extremely good trend in the viral vectors and plasmid DNA manufacturing market. Manufacturers are exploring approaches to streamline and optimize manufacturing approaches to acquire better yields, lessen production timelines, and decorate overall efficiency in reaction to the developing demand for gene healing procedures.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected market valuation for the Viral Vectors and Plasmid DNA Manufacturing Market in 2035?

The projected market valuation for the Viral Vectors and Plasmid DNA Manufacturing Market in 2035 is 1.574 USD Billion.

What was the market valuation in 2024?

The overall market valuation for the Viral Vectors and Plasmid DNA Manufacturing Market was 0.4 USD Billion in 2024.

What is the expected CAGR for the market during the forecast period 2025 - 2035?

The expected CAGR for the Viral Vectors and Plasmid DNA Manufacturing Market during the forecast period 2025 - 2035 is 13.26%.

Which companies are considered key players in the Viral Vectors and Plasmid DNA Manufacturing Market?

Key players in the market include Lonza, Boehringer Ingelheim, Sartorius, Thermo Fisher Scientific, and WuXi AppTec.

What are the main applications driving the market growth?

The main applications driving market growth include Gene Therapy, Vaccine Development, Transgenic Research, and Cell and Gene Editing.

How do the valuations of different types of vectors compare in the market?

In 2024, the valuations were 0.16 USD Billion for Viral Vectors, 0.12 USD Billion for Plasmid DNA, and 0.12 USD Billion for RNA-based Vectors.

What technologies are utilized in the Viral Vectors and Plasmid DNA Manufacturing Market?

Technologies utilized in the market include Viral Transduction, Electroporation, Microinjection, and Liposomal Delivery.

What is the market share of pharmaceutical companies in the end-use segment?

Pharmaceutical companies held a market share of 0.16 USD Billion in the end-use segment in 2024.

What is the projected growth for the Vaccine Development application by 2035?

The projected growth for the Vaccine Development application is expected to reach 0.6 USD Billion by 2035.

How does the market for biotechnology firms compare to that of research institutions?

In 2024, biotechnology firms had a market valuation of 0.12 USD Billion, while research institutions had a valuation of 0.12 USD Billion.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Viral Vectors and Plasmid DNA Manufacturing Market was estimated at 0.4 USD Billion in 2024. The market is projected to grow from 0.453 USD Billion in 2025 to 1.574 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 13.26 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Viral Vectors and Plasmid DNA Manufacturing Market is experiencing robust growth driven by technological advancements and increasing demand for gene therapies.

The market is witnessing a rising demand for gene therapies, particularly in North America, which remains the largest market. Technological advancements in production methods are enhancing efficiency and scalability, especially in the Asia-Pacific region. Collaborative research initiatives are fostering innovation, with gene therapy being the largest segment and vaccine development emerging as the fastest-growing. Key market drivers include the increasing prevalence of genetic disorders and expanding applications in vaccine development, which are propelling market growth.

Viral Vectors and Plasmid DNA Manufacturing Market

CAGR

13.26%

Market Size & Forecast

2024 Market Size	0.4 (USD Billion)
2035 Market Size	1.574 (USD Billion)
CAGR (2025 - 2035)	13.26%
Largest Regional Market Share in 2024	North America

Major Players

<a href="https://www.lonza.com/specialized-modalities/cell-and-gene/viral-vectors">Lonza (CH)</a>, Boehringer Ingelheim (DE), Sartorius (DE), Thermo Fisher Scientific (US), WuXi AppTec (CN), Cobra Biologics (GB), Viva Biotech (CN), Aldevron (US), MilliporeSigma (US), Celerion (US)

Market Trends

The Viral Vectors and Plasmid DNA Manufacturing Market is currently experiencing a notable transformation, driven by advancements in biotechnology and increasing demand for gene therapies. This sector is characterized by a growing emphasis on the development of innovative therapeutic solutions, which are increasingly being recognized for their potential to treat a variety of genetic disorders and cancers. As research institutions and pharmaceutical companies invest heavily in this area, the market is likely to witness a surge in the production capabilities of viral vectors and plasmid DNA. Furthermore, collaborations between academic institutions and industry players appear to be fostering a conducive environment for innovation, thereby enhancing the overall landscape of this market. In addition, regulatory frameworks are evolving to accommodate the rapid advancements in gene therapy technologies. This shift may lead to streamlined approval processes, which could facilitate quicker access to novel treatments for patients. The increasing prevalence of chronic diseases and genetic disorders is also propelling the demand for effective therapeutic options, further driving growth in the Viral Vectors and Plasmid DNA Manufacturing Market. As the market continues to expand, it is essential for stakeholders to remain vigilant regarding emerging trends and technological advancements that could shape the future of this dynamic field.

Rising Demand for Gene Therapies

The growing interest in gene therapies is significantly influencing the Viral Vectors and Plasmid DNA Manufacturing Market. As more therapies receive approval, the need for efficient manufacturing processes becomes paramount. This trend suggests a shift towards scalable production methods that can meet the increasing demand.

Technological Advancements in Production

Innovations in manufacturing technologies are reshaping the landscape of the Viral Vectors and Plasmid DNA Manufacturing Market. Techniques such as continuous manufacturing and improved purification processes are enhancing efficiency and reducing costs, which may lead to broader accessibility of these therapies.

Collaborative Research Initiatives

Partnerships between academic institutions and industry leaders are becoming more prevalent in the Viral Vectors and Plasmid DNA Manufacturing Market. These collaborations are likely to accelerate research and development efforts, fostering innovation and potentially leading to groundbreaking therapeutic solutions.

The ongoing advancements in gene therapy and vaccine development are driving a notable increase in the demand for viral vectors and plasmid DNA manufacturing, suggesting a transformative shift in biopharmaceutical production.

U.S. Food and Drug Administration (FDA)

Viral Vectors and Plasmid DNA Manufacturing Market Market Drivers

Rising Investment in Biotechnology

The surge in investment within the biotechnology sector is a crucial driver for the Viral Vectors and Plasmid DNA Manufacturing Market. Venture capital funding and government grants are increasingly directed towards companies specializing in gene therapy and related technologies. In recent years, the biotechnology sector has attracted billions in investments, reflecting a growing confidence in the potential of gene-based therapies. This influx of capital enables companies to enhance their research and development capabilities, thereby accelerating the production of viral vectors and plasmid DNA. As a result, the market is likely to experience robust growth, driven by the continuous innovation and expansion of therapeutic applications within the Viral Vectors and Plasmid DNA Manufacturing Market.

Growing Demand for Personalized Medicine

The increasing demand for personalized medicine is emerging as a vital driver for the Viral Vectors and Plasmid DNA Manufacturing Market. As healthcare shifts towards tailored treatment approaches, the need for specific gene therapies that cater to individual patient profiles is becoming more pronounced. This trend is supported by advancements in genomic technologies, which enable the identification of unique genetic markers associated with various diseases. The market is likely to expand as healthcare providers seek to implement personalized treatment plans, thereby increasing the utilization of viral vectors and plasmid DNA in therapeutic applications. This evolution in patient care signifies a transformative phase for the Viral Vectors and Plasmid DNA Manufacturing Market, aligning with the broader movement towards precision medicine.

Increasing Prevalence of Genetic Disorders

The rising incidence of genetic disorders is a pivotal driver for the Viral Vectors and Plasmid DNA Manufacturing Market. As more individuals are diagnosed with conditions such as cystic fibrosis, hemophilia, and muscular dystrophy, the demand for effective gene therapies is escalating. This trend is underscored by the fact that approximately 1 in 10 individuals are affected by a rare genetic disorder, which propels the need for innovative treatment solutions. Consequently, pharmaceutical companies are investing heavily in the development of viral vectors and plasmid DNA technologies to address these health challenges. The market is projected to witness substantial growth as healthcare providers seek advanced therapeutic options, thereby enhancing the overall landscape of the Viral Vectors and Plasmid DNA Manufacturing Market.

Regulatory Support for Gene Therapy Products

Regulatory bodies are increasingly providing support for the development and approval of gene therapy products, which is a significant driver for the Viral Vectors and Plasmid DNA Manufacturing Market. Initiatives aimed at streamlining the approval process for gene therapies are being implemented, thereby encouraging companies to invest in the development of viral vectors and plasmid DNA technologies. For instance, the introduction of expedited review pathways has facilitated faster access to the market for innovative therapies. This regulatory environment fosters a conducive atmosphere for research and development, potentially leading to a surge in the number of approved gene therapies. Consequently, the Viral Vectors and Plasmid DNA Manufacturing Market is poised for growth as more products gain regulatory approval.

Expanding Applications in Vaccine Development

The ongoing expansion of applications for viral vectors and plasmid DNA in vaccine development is significantly influencing the Viral Vectors and Plasmid DNA Manufacturing Market. With the increasing focus on preventive healthcare, the utilization of these technologies in creating vaccines for infectious diseases is becoming more prevalent. For instance, the use of viral vectors in the development of vaccines for diseases such as Zika and Ebola has demonstrated their potential. The market is expected to grow as more research institutions and biotech companies explore these applications, with the vaccine segment projected to account for a substantial share of the overall market. This trend indicates a promising future for the Viral Vectors and Plasmid DNA Manufacturing Market as it adapts to meet the evolving needs of public health.

Market Segment Insights

By Application: Gene Therapy (Largest) vs. Vaccine Development (Fastest-Growing)

The application segment of the Viral Vectors and Plasmid DNA Manufacturing Market is dominated by Gene Therapy, which has established itself as the leading force in the industry. Following closely is Vaccine Development, gaining significant traction, particularly in light of recent global health challenges, which has propelled its relevance and urgency. Other applications such as Transgenic Research and Cell and Gene Editing also contribute to the market, but their shares are smaller compared to the robust presence of the primary two. Growth within this segment is largely driven by increasing investments in gene therapy and vaccine research, facilitated by advancements in biotechnology and a broadening understanding of genetic diseases. Moreover, the need for effective treatments and preventive measures, particularly post-pandemic, has highlighted the necessity for innovative biopharmaceutical solutions. The rise of personalized medicine and technology improvements in vector capabilities are also shaping the future of this segment, indicating a dynamic evolution in the market landscape.

Gene Therapy (Dominant) vs. Vaccine Development (Emerging)

Gene Therapy stands as the dominant force in the application segment of the Viral Vectors and Plasmid DNA Manufacturing Market, representing advanced treatments designed to correct or replace faulty genes responsible for disease development. Its established methodologies and significant clinical advancements make it a pivotal element in modern medicine. Conversely, Vaccine Development is emerging rapidly, spurred by the recent demands for novel vaccines that combat evolving viral threats. This sector not only leverages traditional vaccine platforms but also harnesses cutting-edge technologies such as mRNA and viral vector-based vaccines. Together, these segments exemplify a strategic partnership in futuristic healthcare, where Gene Therapy provides groundbreaking solutions for chronic conditions, and Vaccine Development addresses immediate public health needs.

By Type: Viral Vectors (Largest) vs. Plasmid DNA (Fastest-Growing)

In the Viral Vectors and Plasmid DNA Manufacturing Market, Viral Vectors hold the largest market share, driven by their extensive application in gene therapy and vaccine development. The demand for targeted therapies using viral vectors has led to their widespread adoption, creating a significant portion of the market. Meanwhile, Plasmid DNA is positioned as the fastest-growing segment, driven by its increasing use in DNA vaccines and gene editing, reflecting a surge in interest among biotech companies toward these innovative therapies.

Segment Insights: Viral Vectors (Dominant) vs. Plasmid DNA (Emerging)

Viral Vectors dominate the market due to their effectiveness in delivering therapeutic genes into target cells, which positions them as crucial tools in modern medicine. Their adaptability to various types of treatments, such as vaccines and <a href="https://www.marketresearchfuture.com/reports/cancer-biologic-therapy-market-566">cancer biological therapies</a>, contributes to their strong foothold in the sector. Conversely, Plasmid DNA is emerging rapidly as it presents advantages such as ease of production and the ability to induce durable immune responses, particularly in the context of therapeutic and prophylactic vaccines. The technological advancements in manufacturing processes and the growing emphasis on personalized medicine are further propelling the growth of Plasmid DNA, making it an area of increasing interest and investment within the market.

By Technology: Viral Transduction (Largest) vs. Electroporation (Fastest-Growing)

In the Viral Vectors and Plasmid DNA Manufacturing Market, the technology segment displays a varied distribution with Viral Transduction leading the charge. This approach has captivated a significant portion of the market due to its effectiveness in delivering genetic material into host cells. Electroporation, while currently gaining traction, serves as the fastest-growing technology, attracting attention for its efficiency and ease of use in various applications. As the demand for advanced gene therapies and vaccines increases, the growth of these technologies is driven by escalating research activities and favorable regulatory frameworks. Innovations in electroporation techniques are making this method increasingly popular, enabling more efficient cellular transfection. Consequently, as therapeutic applications derive from these technologies expand, market leaders are poised to capitalize on both their established products and new innovations.

Technology: Viral Transduction (Dominant) vs. Electroporation (Emerging)

Viral Transduction is considered the dominant approach in the Viral Vectors and Plasmid DNA Manufacturing Market, offering high efficiency and specificity in gene delivery. It leverages viruses to transfer genetic material, making it particularly advantageous for applications in gene therapies and oncological treatments. This method enjoys significant market share due to its proven efficacy and safety profile. Conversely, Electroporation represents an emerging technique, gaining popularity for its rapid transfection capabilities and simplicity. This method applies an electric field to facilitate the uptake of DNA, presenting a versatile option for various cell types and laboratory settings. As research continues to explore its potential, Electroporation is on the cusp of becoming a significant player in the field.

By End-Use: Pharmaceutical Companies (Largest) vs. Biotechnology Firms (Fastest-Growing)

In the Viral Vectors and Plasmid DNA Manufacturing Market, pharmaceutical companies hold the largest market share, leveraging their established expertise and resources for product development. They are significant consumers of viral vectors and plasmid DNA for therapeutic applications, contributing substantially to the market's size. Conversely, biotechnology firms are rapidly gaining traction, finding innovative applications and opportunities to exploit these biological tools as they strive to advance personalized medicine and biologics. This shift indicates a dynamic distribution of market influence across these end-users. Growth trends reveal that while pharmaceutical companies remain the dominant players in this space, biotechnology firms are emerging as a formidable force. The increasing number of biotechnology startups focusing on gene therapies and vaccine development is driving this growth. Factors such as technological advancements in vector engineering and growing investment in R&D are propelling the market forward, allowing biotechnology firms to expand their footprint and innovate at a pace that is outstripping traditional pharmaceutical approaches.

Pharmaceutical Companies (Dominant) vs. Biotechnology Firms (Emerging)

Pharmaceutical companies dominate the Viral Vectors and Plasmid DNA Manufacturing Market due to their established operational frameworks and extensive experience in drug development. These companies utilize viral vectors and plasmid DNA for a range of applications, including vaccine development and gene therapy, benefiting from their financial capabilities and infrastructure. In contrast, biotechnology firms, while emerging, are characterized by innovation and agility. These companies focus on cutting-edge research, often driven by niche applications that challenge existing paradigms. As more biotechnology firms enter the market, they are introducing novel approaches and methods, making significant contributions to scientific advancements and potentially reshaping future therapeutic landscapes.

Get more detailed insights about Viral Vectors and Plasmid DNA Manufacturing Market Research Report-Forecast to 2035

Regional Insights

North America : Leading Innovation and Investment

North America is the largest market for viral vectors and plasmid DNA manufacturing, holding approximately 45% of the global market share. The region benefits from robust investment in biotechnology, advanced research facilities, and a favorable regulatory environment. The increasing demand for gene therapies and vaccines, particularly post-COVID-19, has accelerated growth. Regulatory bodies like the FDA have streamlined approval processes, further catalyzing market expansion. The United States is the primary driver of this market, with key players such as Thermo Fisher Scientific, Lonza, and Aldevron leading the charge. Canada also contributes significantly, focusing on innovative research and development. The competitive landscape is characterized by collaborations and partnerships among major firms, enhancing capabilities in viral vector production and plasmid DNA manufacturing.

Europe : Regulatory Framework and Growth

Europe is the second-largest market for viral vectors and plasmid DNA manufacturing, accounting for approximately 30% of the global market share. The region's growth is driven by increasing investments in biotechnology and a strong focus on research and development. The European Medicines Agency (EMA) has established clear guidelines for gene therapies, which has encouraged innovation and investment in this sector. The rising prevalence of genetic disorders and the demand for personalized medicine are also significant growth factors. Leading countries in Europe include Germany, France, and the United Kingdom, which host numerous biopharmaceutical companies and research institutions. Key players such as Boehringer Ingelheim and Sartorius are pivotal in advancing manufacturing capabilities. The competitive landscape is marked by strategic collaborations and mergers, enhancing the region's position in the global market.

Asia-Pacific : Rapid Growth and Investment

Asia-Pacific is witnessing rapid growth in the viral vectors and plasmid DNA manufacturing market, holding approximately 20% of the global market share. The region's expansion is fueled by increasing investments in biotechnology, a growing number of clinical trials, and rising healthcare expenditures. Countries like China and India are becoming significant players, supported by government initiatives aimed at boosting the biotech sector. The regulatory environment is evolving, with agencies working to streamline approval processes for new therapies. China is leading the charge in this region, with companies like WuXi AppTec and Viva Biotech making substantial contributions to the market. India is also emerging as a key player, focusing on affordable healthcare solutions and biomanufacturing capabilities. The competitive landscape is characterized by a mix of local and international firms, driving innovation and collaboration in the sector.

Middle East and Africa : Untapped Potential and Growth

The Middle East and Africa (MEA) region is gradually emerging in the viral vectors and plasmid DNA manufacturing market, holding about 5% of the global market share. The growth in this region is primarily driven by increasing healthcare investments, rising awareness of gene therapies, and government initiatives to enhance biomanufacturing capabilities. Countries like South Africa and the UAE are focusing on developing their biotech sectors, supported by favorable policies and funding opportunities. South Africa is leading the market in the MEA region, with a growing number of biotech firms and research institutions. The competitive landscape is still developing, with local companies collaborating with international players to enhance their capabilities. The region's potential for growth is significant, as it seeks to establish itself as a hub for biomanufacturing and innovation in the coming years.

Key Players and Competitive Insights

The Viral Vectors and Plasmid DNA Manufacturing Market is currently characterized by a dynamic competitive landscape, driven by increasing demand for gene therapies and advanced biopharmaceuticals. Key players such as Lonza (CH), Boehringer Ingelheim (DE), and Thermo Fisher Scientific (US) are strategically positioned to leverage their extensive capabilities in bioprocessing and manufacturing. Lonza (CH) has focused on expanding its production capacity, particularly in viral vector manufacturing, to meet the growing needs of its clients in the gene therapy sector. Meanwhile, Boehringer Ingelheim (DE) emphasizes innovation through its recent investments in digital technologies to enhance operational efficiency and product quality. These strategies collectively contribute to a competitive environment that is increasingly centered around technological advancement and operational excellence.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and enhance supply chain resilience. The market appears moderately fragmented, with several players vying for market share while also forming strategic partnerships to bolster their capabilities. This competitive structure allows for a diverse range of offerings, catering to various segments within the biopharmaceutical industry.

In August 2025, Thermo Fisher Scientific (US) announced the opening of a new state-of-the-art facility dedicated to the production of plasmid DNA. This strategic move is expected to significantly enhance their production capacity and streamline operations, thereby positioning them as a leader in the plasmid DNA segment. The facility is designed to support the increasing demand for plasmid DNA in gene therapy applications, indicating Thermo Fisher's commitment to innovation and responsiveness to market needs.

In July 2025, Boehringer Ingelheim (DE) launched a new platform aimed at accelerating the development of viral vector-based therapies. This initiative underscores the company's focus on enhancing its service offerings and providing clients with faster turnaround times for their projects. By investing in this platform, Boehringer Ingelheim is likely to strengthen its competitive edge in the rapidly evolving gene therapy landscape.

In September 2025, Lonza (CH) entered into a strategic partnership with a leading biotech firm to co-develop a novel viral vector for a groundbreaking gene therapy. This collaboration not only highlights Lonza's commitment to innovation but also reflects a broader trend in the industry where partnerships are becoming essential for advancing complex biopharmaceutical products. Such alliances are indicative of a shift towards collaborative innovation in the market.

As of October 2025, the competitive trends in the Viral Vectors and Plasmid DNA Manufacturing Market are increasingly influenced by digitalization, sustainability, and the integration of artificial intelligence in manufacturing processes. Strategic alliances are shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability, thereby redefining the parameters of success in this burgeoning market.

Key Companies in the Viral Vectors and Plasmid DNA Manufacturing Market market include

Industry Developments

Q2 2024: FUJIFILM Diosynth Biotechnologies Opens New Viral Vector Manufacturing Facility in Texas FUJIFILM Diosynth Biotechnologies announced the opening of its new state-of-the-art viral vector manufacturing facility in College Station, Texas, expanding its capacity to support gene therapy and vaccine developers with commercial-scale production.
Q2 2024: Thermo Fisher Scientific Acquires Viral Vector Manufacturer OXGENE Thermo Fisher Scientific completed the acquisition of OXGENE, a UK-based viral vector development and manufacturing company, to strengthen its cell and gene therapy capabilities and expand its viral vector services portfolio.
Q3 2024: Catalent Signs Multi-Year Manufacturing Agreement with Sarepta Therapeutics for Gene Therapy Vectors Catalent entered into a multi-year agreement with Sarepta Therapeutics to manufacture adeno-associated viral (AAV) vectors for Sarepta’s gene therapy programs, enhancing Catalent’s position as a leading contract manufacturer in the sector.
Q2 2024: Aldevron Expands Plasmid DNA Manufacturing Facility in Fargo Aldevron, a leading plasmid DNA manufacturer, announced the expansion of its Fargo, North Dakota facility, increasing its production capacity to meet growing demand from gene therapy and vaccine developers.
Q1 2025: Lonza Appoints New Head of Viral Vector Manufacturing Division Lonza announced the appointment of Dr. Maria Sanchez as the new head of its viral vector manufacturing division, aiming to accelerate innovation and operational efficiency in its gene therapy manufacturing business.
Q2 2025: Pfizer Announces $300 Million Investment in Viral Vector Manufacturing Facility in North Carolina Pfizer revealed plans to invest $300 million in a new viral vector manufacturing facility in Sanford, North Carolina, to support its expanding gene therapy pipeline and meet increasing global demand.
Q1 2024: Vigene Biosciences Secures FDA Approval for Commercial-Scale Viral Vector Production Vigene Biosciences received FDA approval to begin commercial-scale manufacturing of viral vectors at its Rockville, Maryland facility, enabling the company to supply gene therapy developers with clinical and commercial-grade vectors.
Q3 2024: Aldevron and Moderna Announce Strategic Partnership for Plasmid DNA Supply Aldevron and Moderna entered a strategic partnership to supply high-quality plasmid DNA for Moderna’s mRNA vaccine and gene therapy programs, ensuring a reliable supply chain for critical raw materials.
Q2 2025: Charles River Laboratories Acquires Cognate BioServices to Expand Cell and Gene Therapy Manufacturing Charles River Laboratories completed the acquisition of Cognate BioServices, a contract development and manufacturing organization specializing in cell and gene therapy, including viral vector and plasmid DNA production.
Q1 2025: Oxford Biomedica Wins Major Contract to Manufacture Lentiviral Vectors for Novartis Oxford Biomedica secured a significant contract with Novartis to manufacture lentiviral vectors for use in Novartis’ CAR-T cell therapy programs, further solidifying its role as a key supplier in the gene therapy market.
Q2 2024: Thermo Fisher Scientific Launches New Plasmid DNA Manufacturing Platform Thermo Fisher Scientific launched a new plasmid DNA manufacturing platform designed to accelerate the development and production of gene therapies and vaccines, offering scalable solutions for clinical and commercial needs.
Q3 2025: Sartorius Opens Advanced Viral Vector Manufacturing Facility in Germany Sartorius inaugurated a new advanced viral vector manufacturing facility in Göttingen, Germany, to support the growing demand for gene therapy and vaccine development in Europe.

Future Outlook

Viral Vectors and Plasmid DNA Manufacturing Market Future Outlook

The Viral Vectors and Plasmid DNA Manufacturing Market is projected to grow at a 13.26% CAGR from 2024 to 2035, driven by advancements in gene therapies and biopharmaceuticals.

New opportunities lie in:

Expansion of contract manufacturing organizations for viral vector production.Development of scalable plasmid DNA production technologies.Investment in next-generation sequencing for enhanced vector design.

By 2035, the market is expected to be robust, driven by innovation and increasing demand.

Market Segmentation

Viral Vectors and Plasmid DNA Manufacturing Market Type Outlook

Viral Vectors
Plasmid DNA
RNA-based Vectors

Viral Vectors and Plasmid DNA Manufacturing Market End-Use Outlook

Pharmaceutical Companies
Biotechnology Firms
Research Institutions

Viral Vectors and Plasmid DNA Manufacturing Market Technology Outlook

Viral Transduction
Electroporation
Microinjection
Liposomal Delivery

Viral Vectors and Plasmid DNA Manufacturing Market Application Outlook

Gene Therapy
Vaccine Development
Transgenic Research
Cell and Gene Editing

Report Scope

MARKET SIZE 2024	0.4(USD Billion)
MARKET SIZE 2025	0.453(USD Billion)
MARKET SIZE 2035	1.574(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	13.26% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Advancements in gene therapy and personalized medicine drive demand in the Viral Vectors and Plasmid DNA Manufacturing Market.
Key Market Dynamics	Rising demand for gene therapies drives innovation and competition in viral vectors and plasmid DNA manufacturing.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Author

Rahul Gotadki

Assistant Manager

She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Latest Comments

John Doe

john@example.com

This is a great article! Really helped me understand the topic better.

Posted on July 23, 2025, 10:15 AM

Jane Smith

jane@domain.com

Thanks for sharing this. I’ve bookmarked it for later reference.

Posted on July 22, 2025, 7:45 PM

View All